Group items tagged

This initiative will foster collaborative and coordinated efforts to characterize the underlying genetic architecture of diverse neuropsychiatric phenotypes within and across rare genetic disorders and identify the shared genetic risk across rare and idiopathic neuropsychiatric disorders. Projects from multi-disciplinary teams will utilize genome-wide data to comprehensively assess the contribution of genetic variation to the variable expressivity and incomplete penetrance of neuropsychiatric phenotypes across rare genetic disorders. Projects are encouraged to leverage existing resources, cohorts, and collaborative networks with established infrastructure for consistent and high-quality phenotypic data collection and genomic data generation. Projects should seek to enhance the quality of the phenotypic data available for rare genetic disorders by developing or applying phenotyping methodologies that create a pipeline for standardizing assessments and that cut across rare genetic disorders and across developmental time points. Under this initiative, investigators will form a network to facilitate data sharing and harmonization of clinical and genetic data across different studies within the network, as well as accelerate characterization of genotype to phenotype relationships across rare genetic disorders. This network will also generate a resource of bio-samples, as well as phenotypic and genetic data for broader dissemination to the scientific community. This FOA should be used for applications that are not collaborative between sites. Applications requiring two or more collaborating sites to complete the proposed research should apply as a linked set of collaborative U01 applications to the companion collaborative U01 FOA (RFA-MH-19-201). All awards supported under this FOA and the companion collaborative U01 FOA (RFA -MH-19-201) will be governed by the Mental Health Rare Genetic Disease Network (MHRGDN).

This initiative will foster collaborative and coordinated efforts to characterize the underlying genetic architecture of diverse neuropsychiatric phenotypes within and across rare genetic disorders and identify the shared genetic risk across rare and idiopathic neuropsychiatric disorders. Projects from multi-disciplinary teams will utilize genome-wide data to comprehensively assess the contribution of genetic variation to the variable expressivity and incomplete penetrance of neuropsychiatric phenotypes across rare genetic disorders. Projects are encouraged to leverage existing resources, cohorts, and collaborative networks with established infrastructure for consistent and high-quality phenotypic data collection and genomic data generation. Projects should seek to enhance the quality of the phenotypic data available for rare genetic disorders by developing or applying phenotyping methodologies that create a pipeline for standardizing assessments and that cut across rare genetic disorders and across developmental time points. Under this initiative, investigators will form a network to facilitate data sharing and harmonization of clinical and genetic data across different studies within the network, as well as accelerate characterization of genotype to phenotype relationships across rare genetic disorders. This network will also generate a resource of bio-samples, as well as phenotypic and genetic data for broader dissemination to the scientific community.

This notice announces the opportunity to apply for funding under the National Genetics Education and Family Support Program (NGEFSP). The purpose of this program is to increase access to genetic services by promoting and strengthening engagement of individuals and families with, or at risk for, genetic conditions in the genetic health care delivery system.This will be accomplished by funding a program that will: * provide culturally- and linguistically-appropriate education and resources on genetics and genetic conditions to families; * provide support for individuals and families with, or at risk for, genetic conditions so that they can be equal partners in their health care; * train individuals and families with, or at risk for, genetic conditions to become family leaders within the genetic health care delivery system and the Regional Genetics Networks (RGNs); and * provide technical assistance to RGNs on how best to incorporate family leaders into their programs and reach underserved populations.1

Projects from multi-disciplinary teams will utilize genome-wide data to comprehensively assess the contribution of genetic variation to the variable expressivity and incomplete penetrance of neuropsychiatric phenotypes across rare genetic disorders. Projects are encouraged to leverage existing resources, cohorts, and collaborative networks with established infrastructure for consistent and high-quality phenotypic data collection and genomic data generation. Projects should seek to enhance the quality of the phenotypic data available for rare genetic disorders by developing or applying phenotyping methodologies that create a pipeline for standardizing assessments and that cut across rare genetic disorders and across developmental time points. Under this initiative, investigators will form a network to facilitate data sharing and harmonization of clinical and genetic data across different studies within the network, as well as accelerate characterization of genotype to phenotype relationships across rare genetic disorders. This network will also generate a resource of bio-samples, as well as phenotypic and genetic data for broader dissemination to the scientific community.   

This Funding Opportunity Announcement (FOA) seeks to stimulate and expand research on the interplay of genetic and environmental factors in the genesis, course, and outcomes of substance and alcohol use disorders (SUDs). Previous work in genetic epidemiology and molecular genetics has established that SUDs are highly heritable, developmental disorders with important genetic substrates.Building on these findings, new studies using genetically informative approaches are needed to elucidate the complex interplay of genetic and environmental factors in developmental trajectories of SUDs and comorbid conditions, deepen and refine phenotypic definitions of SUDs, and meet the methodologic challenges of the field.Such studies hold great potential to promote understanding of the true contributions of both genetic and environmental factors to initiation, progression, comorbidity, adverse outcomes, and cessation of SUDs; to elucidate mechanisms of risk; and to enhance opportunities for translation to treatment, prevention, gene-finding and molecular studies.

This Funding Opportunity Announcement (FOA) seeks to stimulate and expand research on the interplay of genetic and environmental factors in the genesis, course, and outcomes of substance and alcohol use disorders (SUDs). Previous work in genetic epidemiology and molecular genetics has established that SUDs are highly heritable, developmental disorders with important genetic substrates.Building on these findings, new studies using genetically informative approaches are needed to elucidate the complex interplay of genetic and environmental factors in developmental trajectories of SUDs and comorbid conditions, deepen and refine phenotypic definitions of SUDs, and meet the methodologic challenges of the field.Such studies hold great potential to promote understanding of the true contributions of both genetic and environmental factors to initiation, progression, comorbidity, adverse outcomes, and cessation of SUDs; to elucidate mechanisms of risk; and to enhance opportunities for translation to treatment, prevention, gene-finding and molecular studies.

The Genetics Society was founded by William Bateson in 1919 and is one of the oldest "learned societies" devoted to Genetics in the world. Its membership of over 1700 consists of most of the UK's active professional geneticists, including teachers, researchers and students.  The research field should be one from which results would typically be suitable for publication in the Society's journal Heredity: -population genetics (including human) -genomics -functional genomics and proteomics -biometrical and statistical genetics -ecological and evolutionary genetics -animal and plant breeding -cytogenetics

The Genetics or Epigenetics of Substance Use Disorders Avenir Award program supports early stage investigators proposing highly innovative studies that open new areas of research for the genetics or epigenetics of addiction. These may be novel methods or approaches that can potentially be applied to the analysis of the genetics or epigenetics of addiction. Investigators outside the field of addiction interested in applying their novel approaches to the genetics or epigenetics of addiction are encouraged to apply. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field of genetics or epigenetics of substance use disorders.

In recognition of the critical role DeLill Nasser played for the discipline and for her love of genetics, in 2001 The Genetics Society of America established The DeLill Nasser Award for Professional Development in Genetics, an award for graduate students and postdoctoral trainees, to support travel costs for young geneticists to attend national and international meetings and enroll in laboratory courses. The Award is named for long-time GSA member and National Science Foundation Program Director in Eukaryotic Genetics, DeLill Nasser.

This Funding Opportunity Announcement (FOA) requests submission of applications for the National Institute on Aging (NIA) Late Onset of Alzheimer's Disease (LOAD) Family Based Study (FBS). Analysis of families that are multiply affected with Alzheimer's disease (AD) provides distinct advantages for characterizing the impact of genetic variants on disease risk. First, multiplex families are likely to be enriched for genetic variants associated with increased risk, providing increased statistical power to estimate the effects. Second, analysis of multiply affected families provides insight into the remaining unknown genetic influences (i.e., the "residual heritability") as well as antecedent modifying factors that interact with identified genetic variants to influence disease risk. Third, family members at risk are followed at regular intervals, facilitating prospective investigation of the effects of the genetic variants on age-at-onset as well as the modifying effects of antecedent risk and protective factors. Finally, family data can provide information regarding the influence of known variants on the rate of disease progression and the residual heritability of disease progression.

The National Institute on Drug Abuse (NIDA) will solicit proposals from qualified organizations capable of maintaining and expanding the NIDA Center for Genetic Studies. In this effort, the contractor will be required to: (1) Receive de-identified clinical, diagnostic, pedigree structure, environmental exposure information and other phenotypic data along with blood samples or other biospecimens from funded grants and/or contracts supporting research on the genetics of addiction and addiction vulnerability; (2) Process these data and materials to create databases, serum, DNA, RNA, and cell lines; (3) Widely distribute all data and materials in the NIDA Human Genetics Initiative to qualified investigators in the scientific community in a cost effective manner; (4) Maintain storage of data and biomaterials; (5) As stipulated by NIDA staff, perform microarray typing on pre-existing and/or new de-identified biospecimens; (6) As stipulated by NIDA staff, perform high-throughput sequencing on pre-existing and/or new de-identified biospecimens for genomic and/or epigenomic analyses; (7) Support the creation of reprogrammed cellular derivatives, such as induced pluripotent stem cells (iPSCs) to facilitate the molecular and cellular study of brain development and addiction processes; (8) Create a cyberinfrastructure that enables interoperability and full access to distributed data, software and other information science resources as well as research summaries and outbound links for all addiction related studies available through the NIH database of Genotype and Phenotype (dbGaP) system; and (9) Faciliate NIDA genetic studies data (both genotype and phenotype) being uploaded into NIH databases such as BioSample, and the dbGaP systems.

Nominations for the Genetics Prize are invited annually from the field of genetics. Nominations may be submitted by individuals, organizations, and institutions that are active in or have an appreciation for contemporary genetic research or problems.

The purpose of this funding opportunity announcement (FOA) is to support projects that implement creative, efficient molecular epidemiologic approaches that incorporate individual genetic information, including polygenic as well as specific genetic risk variants, in existing large, population-based cohorts, registries and/or health systems to conduct analyses that advance our understanding of the complex etiology of severe mental disorders. The ultimate objective of this funding opportunity is the elucidation of the complex interplays of genetic (e.g., polygenic) risk, in addition to specific risk loci and networks, and environmental factors, in human populations, which will lead to better understanding, diagnosis, and ultimately treatment of mental disorders.

The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC), in collaboration with the International IBD Genetics Consortium, has identified about 200 susceptibility loci for IBD. The IBDGC has recently been awarded renewed funding to identify causal genes and genetic variants within these loci, and to elucidate the mechanisms through which they contribute to the pathophysiology of IBD. However, the IBDGC's current resources permit them to explore the functions of only a limited set of genes within a limited set of physiological domains. The purpose of this Funding Opportunity Announcement (FOA) is to expand the number of genes and range of IBD-related phenotypes and physiological domains under study by means of collaborations of the IBDGC with investigators with expertise complementary to that of their own members. Proposed studies must not duplicate studies either ongoing or already completed by the IBDGC. Multi-site clinical trials will not be considered responsive to this FOA.

The National Institute on Alcohol Abuse and Alcoholism is publishing a Funding Opportunity Announcement (FOA) to seek applications on novel genetic mechanisms underlying the development of tolerance and the progression to alcohol use disorder. Alcohol use disorders are complex, multifactorial, and influenced both by genetic and environmental factors. The purpose of this FOA is to stimulate and support efforts on identifying genetic, genomic and epigenetic factors contributing to the development of sensitivity and tolerance to alcohol.

There are two main purposes of the Rat Opioid Genome Project. The first is to tease out genetic, genomic, and molecular (epi)genetic variants that underlie phenotypes associated with distinct stages along the opioid use disorder (OUD) trajectory to identify potential targets for future interventions at early stages along the trajectory. The second is to identify genetic, genomic, and molecular (epi)genetic variants underlying comorbid conditions and/or phenotypes that can be used to develop therapeutics to save lives of people who are at the end stages of the OUD trajectory.

This Funding Opportunity Announcement (FOA) is a limited competition FOA soliciting a cooperative agreement (U10) application from investigators currently supported under an existing study, entitled "Collaborative Study of the Genetics of Alcoholism (COGA)" to (i) identify genetic variants that affect the susceptibility to develop alcohol dependence in adult and adolescent populations, (ii) determine molecular and functional mechanisms of these variants, (iii) identify and characterize gene x gene and gene x environment interactions leading to alcoholism, (iv) develop and refine phenotypes that will facilitate genetic analysis,  (v) perform prospective studies of COGA probands.

This FOA encourages applications for research projects that identify and/or validate chromosomal loci and variations in genes that are associated with vulnerability to addiction and that inform the likelihood of responsiveness to treatment. Applications that propose to examine intermediate phenotypes or endophenotypes to assess the molecular genetics of drug addiction, addiction vulnerability and/or their associated co-morbidities and how they are related to drug addiction are especially encouraged. Also encouraged are genetic as well as computational and large-scale genomic approaches, which may include but are not limited to linkage, linkage disequilibrium, case-control or family-based studies, and integration of data from other databases that may supplement substance abuse genetics and genomics data. Data may be collected from the general population, special populations, recent admixed populations, and/or animal models. Secondary data analysis of data collected from the general population, special populations, recent admixed populations, and/or animal models is also appropriate for this announcement. Investigators are encouraged to include, as a component of their project and as appropriate, gene x gene interactions, gene x environment interactions, gene x environment x development interactions, pharmacogenetics, and non-human models.

The purpose of this Funding Opportunity Announcement (FOA)is to encourage research into dental, oral, and craniofacial diseases and disorders for which there is evidence for genetic heritability but for which we do not have a strong understanding of the genetics/genomics of the disease or disorder. Applicable areas of investigation include identification of promising areas of the genome, and characterization and elucidation of the function(s) of genetic variants that affect disease risk in humans. The ultimate goal of these studies will be to drive development of effective diagnostic, therapeutic, and preventive approaches.

Background: Kuenzler's Hedgehog Cactus (Echinocereus fendleri var. kuenzleri) is a federally listed species under the Endangered Species Act (ESA). It shares many similarities with a common species, Fendler's Hedgehog Cactus (Echinocereus fendleri var. fendleri) and with many intermediates. This has caused confusion for land managers. The BLM management of Kuenzler's Hedgehog Cactus impacts the multiple uses (i.e. public land users) across the landscape as it restricts land management decisions in order to conserve the imperiled species. Currently, there is no information on the genetic differences of the Kuenzler's Hedgehog Cactus, the Fendler's Hedgehog Cactus, and intermediaries. Without this information it is difficult to determine importance of populations in order to prioritize recovery actions to enable the species to be de-listed. The use of the most current genetic methods for defining species, plastome sequencing, microsatellite development and genotyping, and ddRAD sequencing is needed to accurately determine whether the two species and associated intermediates are in fact the same. If studies show there are two different varieties it will be important to understand how the different Kuenzler's Hedgehog Cactus populations are related to each other across the landscape. This information can help the BLM prioritize populations according to rarity of the element occurrences. The objective of this project is to determine the genetic differences and similarities between Kuenzler's Hedgehog Cactus (all known element occurrences), Fendler's Hedgehog Cactus, and associated intermediates as well as the differences in population structure of the element occurrences of Kuenzler Hedgehog Cactus across the landscape in order to assist with land management decisions and potential de-listing of the species.